Allergan Announces Civil Resolution Concluding Federal Investigation into Forest Sales & Marketing Practices

DUBLIN, Dec. 15, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its indirect subsidiaries Forest Laboratories, LLC and Forest Pharmaceuticals, Inc. (collectively, "Forest") have reached a civil resolution with the federal government, concluding a previously disclosed federal investigation into certain sales and marketing practices involving three Forest products, Bystolic^®, Savella^® and Namenda^®, during the time period January 1, 2008 through December 31, 2011. The period in question is prior to the leadership of the Company under the current management team.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

In addition, Forest has agreed to enter into settlements with state Medicaid programs (the "Settling States") in connection with the same investigation.  The settlement will also resolve a related qui tam litigation pending in the United States District Court for the Eastern District of Wisconsin, 12-CV-366. 

Under the terms of the settlement agreement, Forest will pay a total of $38,000,000 to the federal government and any Settling States to resolve all civil claims.  The settlements will resolve claims stemming from instances in which Forest allegedly lacked adequate controls over payments made to physicians for conducting speaker programs.  Forest Laboratories, LLC previously recorded charges for the entire settlement amount in connection with the government's investigation.  The agreement will not affect Allergan's ongoing business with any customers, including the government.

"At Allergan, we are committed to patients and the medical professional community we serve.  We strive to ensure that patients and their doctors are appropriately educated about our medicines to ensure that they can be used in the right patients for the right conditions," said Jonathon Kellerman, Executive Vice President, Global Chief Compliance Officer.  "We have a strong Compliance organization that ensures that our policies and procedures are, and will remain, best-in-class and ensures that we continue to run our business in full compliance with all laws and regulations as well as the high ethical standards we have set for Allergan."

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

CONTACTS:

ALLERGAN
INVESTORS:
Lisa DeFrancesco
(862) 261-7152

MEDIA:
Mark Marmur
(862) 261-7558

SOURCE Allergan plc

Related Links

http://www.allergan.com